Ana Caroline Zimmer Gelatti

LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

Jeffrey D. Bradley, Shunichi Sugawara, K.H. Lee et al. · ESMO Open · 2024 · 61 citations · Full text

Final Results, Radiation Medicine, Consolidation D +14

LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

B. Besse, SH Lee, Shun Lü et al. · Annals of Oncology · 2024 · 38 citations · Full text

Lba55 Mechanisms, Oncology, Lazertinib Versus Osimertinib +10

Lung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group

Clarissa Baldotto, Ana Caroline Zimmer Gelatti, Arthur Accioly et al. · Clinics · 2020 · 36 citations · Full text

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

Fabrice Barlési, Byoung Chul Cho, Sarah B. Goldberg et al. · Future Oncology · 2024 · 31 citations · Full text

Comprehensive genomic profiling of <scp>Brazilian</scp> non‐small cell lung cancer patients (<scp>GBOT</scp> 0118/<scp>LACOG0418</scp>)

Eldsamira Mascarenhas, Ana Caroline Zimmer Gelatti, Luiz H. Araujo et al. · Thoracic Cancer · 2020 · 28 citations · Full text